8-K 1 a8kq22012.htm FORM 8-K 8K Q22012




  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
  
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 26, 2012
 

 
ENDOLOGIX, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-28440
 
68-0328265
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
 
 
 
11 Studebaker, Irvine, CA
 
92618
(Address of principal executive offices)
 
(Zip Code)
Registrant's telephone number, including area code: (949) 595-7200

 
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 





Item 2.02 Results of Operations and Financial Condition.
On July 26, 2012, Endologix, Inc. ("Endologix") issued a press release to report its financial results for the three and six months ended June 30, 2012. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
On July 26, 2012, Endologix held a conference call with analysts and investors, the transcript of which is furnished as Exhibit 99.2 and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1 and 99.2, is furnished pursuant to Item 2.02 and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by a specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

Exhibit
Number              Description
99.1                Press Release dated July 26, 2012.
99.2                Transcript of Conference Call held on July 26, 2012.

 






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
ENDOLOGIX, INC.
 
 
 
 
 
 
Date: July 26, 2012 
 
 
/s/ Robert J. Krist
 
 
 
 
Robert J. Krist
 
 
 
 
Chief Financial Officer
 







EXHIBIT INDEX
Exhibit
Number            Description
99.1                Press Release dated July 26, 2012.
99.2                Transcript of Conference Call held on July 26, 2012.